News

Osteotech has announced that it has completed enrollment for the clinical trial of DuraTech BioRegeneration Matrix. DuraTech, used to repair dura mater during cranial surgical procedures, is based

FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed

“Following the Annual General Meeting of the Company yesterday, the Board is pleased to recognize Livleen for her outstanding financial leadership in the first half of 2009,” said

InteKrin has declared Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans. The study demonstrated that once a day oral treatment with

Transdel Pharmaceuticals and JH Direct have entered into a licensing agreement, providing JH Direct with the exclusive worldwide rights to Transdel’s anti-cellulite cosmeceutical product. Under the agreement, JH

Bio-Bridge Science has declared that its wholly-owned subsidiary, Bio-Bridge Science has entered into a joint venture contract with JR Scientific to form a new cell culture medium joint

Cannabis has announced that the Company has received its CAGE/NCAGE Code: 5FZM9 certification through Central Contracting Registration (CCR). Steve Kubby, President and CEO of Cannabis, said: “With this

Vitro declared that it has received US Patent number 7527971 entitled, “Generation and Differentiation of Adult Stem Cells.” The patent provides protection to a specific cell line derived

MDRNA announced that it has obtained full FDA approval of its Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis. Calcitonin-salmon nasal